



Kilitch Drugs (India) Ltd.

Admin. Off. : 37, Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai - 400 088.

• Tel. : +91-22-6121 4100 • Fax : +91-22-6703 1658

Regd. Off. : C-301/2, M.I.D.C., T.T.C. Industrial Area, Pawane Village, Navi Mumbai - 400 705, Maharashtra

& Factory • Tel. : +91-22-6514 4185 / 2768 0913 • Fax : +91-22-2768 0912

• E-mail : info@kilitch.com • Website : www.kilitch.com

May 30, 2013.

To,
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051.

Respected Sir,

Scrip Code : KILITCH

Sub: OUTCOME OF THE BOARD MEETING HELD ON THURSDAY, MAY 30, 2013.

With reference to the above captioned subject, we wish to intimate your esteemed exchange that as decided in the Meeting of the Board of Directors of the Company held today, i.e. on Thursday, May 30, 2013 at its Administrative Office at Mumbai, for which intimation was already given to you, the Board of Directors has:

- Approved and taken on record the Audited Financial Results of the Company for the quarter and year ended March 31, 2013.

The above intimation is given to you for your record.

Thanking You,

Yours faithfully,

For KILITCH DRUGS (INDIA) LIMITED

MUKUND MEHTA
MANAGING DIRECTOR



KILITCH DRUGS (INDIA) LIMITED

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND TWELVE MONTHS ENDED 31ST MARCH 2013

PART I

Rs. In lacs

Particulars	STAND ALONE				
	3 MONTHS ENDED	PRECEDING 3 MONTHS	CORRESPONDING 3 MONTHS	TWELVE MONTH	TWELVE MONTH
	31ST MARCH 2013	ENDED 31ST DEC 2012	ENDED 31ST MARCH 2012	ENDED	ENDED
	AUDITED	UNAUDITED	IN THE PREVIOUS YEAR UNAUDITED	31ST MARCH 2013 AUDITED	31ST MARCH 2012 AUDITED
1 Income from operations					
(a) Net Sales/Income from operations (net of Excise)	783.25	344.88	1639.42	3199.01	10660.92
(b) Other operating income	119.07	0.00	0.00	119.07	25.07
Total income from Operations (Net)	902.33	344.88	1639.42	3318.08	10685.99
2 Expenses					
(a) Cost of materials consumed	704.34	157.91	1558.72	2659.83	7058.99
(b) Purchased of Stock-in-trade					
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1.68	23.39	(93.42)	26.13	135.13
(d) Employee benefits expenses	77.30	106.72	148.39	303.45	499.78
(e) Depreciation and amortisation expenses	24.45	32.83	94.36	122.90	483.37
(f) Other expenses (Any item exceeding 10% of the expenses relating to continuing operations to be shown separately)	187.30	167.77	719.17	695.89	1575.64
Total Expenses	995.07	488.62	2427.22	3808.20	9752.91
Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(92.74)	(143.74)	(787.80)	(490.12)	933.08
3 Other Income	123.45	207.19	91.67	915.05	110.25
Profit / (Loss) from ordinary activities before finance cost and exceptional items (3+4)	30.71	63.45	(696.13)	424.93	1043.33
6 Finance Costs	(5.25)	0.00	114.06	1.91	295.33
Profit / (Loss) from ordinary activities after finance cost but before exceptional items (5-6)	35.97	63.45	(810.19)	423.02	748.00
8 Exceptional Items	0.00	0.00	0.00	0.00	(1552.82)
9 Profit / (Loss) from ordinary activities before tax (7+8)	35.97	63.45	(810.19)	423.02	(804.82)
10 Tax Expenses	(2.71)	0.00	0.00	(0.71)	2105.00
11 Net Profit / (Loss) from ordinary activities after tax (9-10)	38.68	63.45	(810.19)	423.73	(2909.82)
Extra Ordinary Items (net of tax expenses Rs. Lakhs)	95.46	0.00	8703.15	95.46	10704.79
12 Net Profit / (Loss) for the period (11+12)	(56.78)	63.45	7892.96	328.27	7794.97
14 Share of Profit / (Loss) of associates	0.00	0.00	0.00	0.00	0.00
15 Minority interest	0.00	0.00	0.00	0.00	0.00
Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)	(56.78)	63.45	7892.96	328.27	7794.97
17 Paid-Up equity share capital	1323.18	1323.18	1323.18	1323.18	1323.18
(Face Value of the Share shall be indicated Rs.10/-)					
Reserve excluding Revaluation Reserve as per Balance sheet of previous accounting year				10582.00	10253.71



19.1	Earnings per share (before extra ordinary items) (In Rs.)					
	(of Rs.10 /each) (not annualised):					
	(a) Basic	0.29	0.48	(6.12)	3.20	(21.99)
	(b) Diluted	0.29	0.48	(6.12)	3.20	(21.99)
19.2	Earnings per share (after extra ordinary items) (In Rs.)					
	(of Rs.10 /each) (not annualised):					
	(a) Basic	(0.43)	0.48	59.79	2.47	58.91
	(b) Diluted	(0.43)	0.48	54.35	2.47	53.68

See accompanying note to the financial results

PART II

	Particulars	3 MONTHS ENDED	PRECEEDING 3MONTHS	CORRESPONDING	YEAR TO DATE	YEAR TO DATE FIGURES
		31ST MARCH 2013	ENDED 31ST DEC 2012	3MONTHS ENDED	CURRENT PERIOD ENDED	PREVIOUS YEAR ENDED
				31ST MARCH 2012	31ST MARCH 2013	31ST MARCH 2012
		AUDITED	UNAUDITED	UNAUDITED	AUDITED	AUDITED
A	PARTICULARS OF SHAREHOLDING					
1	Public shareholding					
	Number of shares	4706393.00	4706393	4706393	4706393	4706393
	Percentage of shareholding	35.57	35.57	35.57	35.57	35.57
2	Promoters and Promoter Group Shareholding					
a)	Pledge / Encumbered					
	Number of shares					
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)					
	Percentage of shares (as a % of the total share capital of the company)					
b)	Non- encumbered					
	Number of shares	8525435.00	8525435	8525435	8525435	8525435
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	1.00	100%	100%	100%	100%
	Percentage of shares (as a % of the total share capital of the company)	64.43	64.43	64.43	64.43	64.43

Particulars	3 months ended 31st March 2013
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	NIL
Received during the quarter	31
Disposed of during the quarter	31
Remaining unresolved at the end of the quarter	NIL

For KILITCH DRUGS (INDIA), LTD

[Signature]

Director

KILITCH DRUGS (INDIA) LIMITED

STATEMENT OF AUDITED FINANCIAL RESULT FOR THE TWELVE MONTHS ENDED 31ST MARCH 2013

(Rupees in Lakhs)

A	Statement of Assets and Liabilities	As at 31st March 2013	As at 31st March 2012
EQUITY AND LIABILITIES			
1 Shareholders Funds			
(a) Share Capital	1,323.18	1,323.18	
(b) Reserve and Surplus	10,582.00	10,253.71	
(c) Money received against share warrants	0.00	0.00	
Sub-total - Shareholders' Funds	11,905.18	11,576.89	
2 Share application money pending allotment	0.00	0.00	
3 Minority Interest	0.00	0.00	
4 Non-current liabilities			
(a) Long-term borrowings	0.00	0.00	
(b) Deferred tax liabilities (net)	25.43	26.14	
(c) Other long-term liabilities	37.03	37.03	
(d) Long term provisions	0.00	0.00	
Sub Total-Non- current liabilities	62.46	63.17	
5 Current liabilities			
(a) Short-term borrowings	0.00	876.91	
(b) Trade Payables	1,347.76	478.61	
(c) Other current liabilities	326.70	124.98	
(d) Short- term provisions	36.30	4,644.78	
Sub Total- current liabilities	1,710.76	6,125.28	
TOTAL- EQUITY AND LIABILITIES	13,678.40	17,765.34	
B ASSETS			
1 Non-current assets			
(a) Fixed Assets	887.40	847.24	
(b) Goodwill on consolidation	0.00	0.00	
(c) Non-current investments	71.58	441.08	
(d) Deferred tax assets (net)	0.00	3.00	
(e) Long-term loans and advances	111.83	24.59	
(f) Other non-current assets	0.00	0.00	
Sub Total-Non- current assets	1,070.81	1,312.91	
2 Current assets			
(a) Current investments	10,827.71	13,577.37	
(b) Inventories	153.92	193.81	
(c) Trade receivables	1,239.79	1,447.19	
(d) Cash and cash equivalents	294.07	1,164.28	
(e) Short-term loans and advances	29.79	20.10	
(f) Other current assets	62.31	49.68	
Sub Total- current assets	12,607.59	16,452.43	
TOTAL- ASSETS	13,678.40	17,765.34	

See accompanying note to the financial results

Notes:

1. The above audited results after being reviewed by the Audit Committee and have been approved and taken on record by the Board of Directors at the meeting held on 30th May 2013
2. During the Financial year 2012-2013, the main manufacturing activity of the Company has substantially reduced as the Company had hired out its business under Business Transfer and Product Transfer Agreements, majority of its products to Akorn India Private Limited.
3. Results of the quarter ended March 2012, and year ended 31st March 2012, include operations of HP plant which was sold to M/s Akorn India Private Limited on slump sale basis on 28th February 2012



4. The Company has only one primary reportable segment-Pharmaceuticals.

5. On 21/09/2012, 66,29,342 Equity shares (50.10%) of the Company was acquired by Kilitch Pharma (Co) Ltd (a company in which the Directors are substantially interested)

6. The figures for the last quarter are the balancing figures between the audited figures in respect of the full financial year and the year to date figures upto the third quarter of the financial year.

7. The previous years/period figures have been regrouped and reclassified wherever required to conform with current year/period figures.

Place Mumbai
Date: 30th May 2013



By and on Behalf of the Board
For Kilitch Drugs (India) Ltd.

Mukund P Mehta
Managing Director